Page 261 - medicina-integrativa_compress

CAPÍTULO 23 HEPATITIS CRÓNICA 255

90. Hezode C, Roudot-Thoraval F, Nguyen S, et al: Daily cannabis 106. Yee GC, Stanley DL, Pessa LJ, et al: Effect of grapefruit juice on
smoking as a risk factor for progression of fibrosis in chronic blood cyclosporin concentration. Lancet 345:955-956, 1995.
hepatitis C. Hepatology 42:63-71, 2005. 107. Corrao G, Ferrari PA: Exploring the role of diet in modifying the
91. Redlich CA, Beckett WS, Sparer J, et al: Liver disease associated with effect of known disease determinants: Application to risk factors of
occupational exposure to the solvent dimethylformamide. Ann liver cirrhosis. Am J Epidemiol 142:1136-1146, 1995.
Intern Med 108:680-686, 1988. 108. Caughey GE, Mantzioris E, Gibson RA, et al: The effect of human
92. Longnecker MP, Rogan WJ, Lucier G: The human health effect of necrosis factor alpha and interleuken 1-beta production of diets
DDT and PCBs and an overview of organochlorines in public health. enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin
Annu Rev Public Health 18:211-244, 1997. Nutr 63:116-122, 1996.
93. Michalek JE, Ketchum NS, Alchtar FZ: Postservice mortality of US 109. Cooper R, Morre DJ, Morre DM: Medicinal benefits of green tea: II.
Air Force veterans occupationally exposed to herbicides in Vietnam: Review of anticancer properties. J Altern Complement Med
Fifteen-year follow-up. Am J Epidemiol 148:786-792, 1998. 11:639-652, 2005.
94. Wallman KE, Morton AR, Goodman C, et al: Randomised 110. Piazza M, Guadagnino V, Picciotto G, et al: Effect of (+)-cyanidanol-3
controlled trial of graded exercise in chronic fatigue syndrome. in acute HAV, HBV and non-A, non-B viral hepatitis. Hepatology
Med J Aust 180:444-448, 2004. 3:45-49, 1983.
95. Dunn AL, Trivedi MH, Kampert JB, et al: Exercise treatment for 111. Gloro R, Hourmand-Ollivier I, Mosquet B, et al: Fulminant hepatitis
depression: Efficacy and dose response. Am J Prev Med 28:1-8, during self-medication with hydroalcoholic extract of green tea. Eur
2005. J Gastroenterol Hepatol 17:1135-1137, 2005.
96. Fairey AS, Courneya KS, Field CJ, et al: Randomized controlled trial 112. Abu el Wafa Y, Benavente Fernandez A, Talavera Fabuel A, et al:
of exercise and blood immune function in postmenopausal breast [Acute hepatitis induced by Camellia sinensis (green tea)].
cancer survivors. J Appl Physiol 98:1534-1540, 2005. Ann Med Int 22:298, 2005.
97. Smith TP, Kennedy SL, Fleshner M: Influence of age and physical 113. Department of Health and Human Services, National Toxicology
activity on the primary in vivo antibody and T cell-mediated Program. Report on Carcinogens, 11th ed. As of October 2005,
responses in men. J Appl Physiol 97:491-498, 2004. available at ntp.niehs.nih.gov/index.cfm?objectid=72016262-
98. Fernandez-Rodriguez CM, Gutierrez ML, Serrano PL, et al: Factors BDB7-CEBA-FA60E922B18C2540.
influencing the rate of fibrosis progression in chronic hepatitis C. 114. Horiike S, Kawanishi S, Kaito M, et al: Accumulation of
Dig Dis Sci 49:1971-1976, 2004. 8-nitroguanine in the liver of patients with chronic hepatitis C.
99. Ortiz V, Berenguer M, Rayon JM, et al: Contribution of obesity J Hepatol 43:403-410, 2005.
to hepatitis C-related fibrosis progression. Am J Gastroenterol 115. Lee SJ, Kim YG, Kang KW, et al: Effects of colchicine on liver
97:2408-2414, 2002. functions of cirrhotic rats: Beneficial effects result from stellate cell
100. Solis-Herruzo JA, Perez-Carreras M, Rivas E, et al: Factors inactivation and inhibition of TGF beta 1 expression. Chem Biol
associated with the presence of nonalcoholic steatohepatitis in Interact 147:9-21, 2004.
patients with chronic hepatitis C. Am J Gastroenterol 100: 116. Adhami JE, Baho J: Treatment with colchicine and survival of
1091-1098, 2005. patients with ascitic cirrhosis: A double-blind randomized trial.
101. Harrison SA, Brunt EM, Qazi RA, et al: Effect of significant Panminerva Med 40:75-81, 1998.
histologic steatosis or steatohepatitis on response to antiviral 117. Terrault NA: Sexual activity as a risk factor for hepatitis C.
therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatology 36(Suppl 1):S99-S105, 2002.
Hepatol 3:604-609, 2005. 118. Saadeh S, Cammell G, Carey WD, et al: The role of liver biopsy
102. Akuta N, Suzuki F, Suzuki Y, et al: Hepatocyte steatosis is an in chronic hepatitis C. Hepatology 33:196-200, 2001.
important predictor of response to interferon (IFN) monotherapy 119. de Santana NP, de Freitas LA, Lyra AC, et al: Liver histological
in Japanese patients infected with HCV genotype 2a: Virological alterations in patients with chronic hepatitis C and normal ALT
features of IFN-resistant cases with hepatocyte steatosis. J Med levels in the city of Salvador, Northeast-Brazil. Braz J Infect Dis
Virol 75:550-558, 2005. 9:134-141, 2005.
103. Bonnesen C, Eggleston IM, Hayes JD: Dietary indoles and 120. Sheth SG, Flamm SL, Gordon FD, Chopra S: AST/ALT ratio predicts
isothiocyanates that are generated from cruciferous vegetables can cirrhosis in patients with chronic hepatitis C virus infection. Am J
both stimulate apoptosis and confer protection against DNA Gastroenterol 93:44-48, 1998.
damage in human colon cell lines. Cancer Res 61:6120-6130, 121. Heathcote EJ, Keeffe EB, Lee SS, et al: Re-treatment of chronic
2001. hepatitis C with consensus interferon. Hepatology 27:1136-1143, 1998.
104. Nho CW, Jeffery E: The synergistic upregulation of phase II 122. Moskovitz DN, Manoharan P, Heathcote EJ: High-dose consensus
detoxification enzymes by glucosinolate breakdown products in interferon in nonresponders to interferon alpha-2b and ribavirin
cruciferous vegetables. Toxicol Appl Pharmacol 174:146-152, with chronic hepatitis C. Can J Gastroenterol 17:479-482, 2003.
2001. 123. Blatt LM, Mutchnick MG, Tong MJ, et al: Assessment of hepatitis C
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
105. Crowell PL, Gould MN: Chemoprevention and therapy of cancer by virus RNA and genotype from 6807 patients with chronic hepatitis C
D-limonene. Crit Rev Oncogen 5:1-22, 1994. in the United States. J Viral Hepat 7:196-202, 2000.